Articles

Find an Article

Filter articles

Showing 651 to 660 of 666 results

Patenting genes and diagnostics

US01-05-2011Simon O’Brien and David Gass

As biotechnology patents continue to grow in importance, uncertainty remains on both sides of the Atlantic as to exactly what is patentable. Simon O’Brien and David Gass take a look.

Attacking the validity of selection patents

Canada01-05-2011Katie Wang

The Canadian Federal Court of Appeal recently considered whether ‘invalid selection’ can be an independent ground for invalidating selection patents. Katie Wang looks at the implications.

The role of the function of DNA sequence before and after grant

01-05-2011Caroline Pallard and Bart Swinkels

Recent European decisions have provided much to think about for practitioners concerned with DNA sequences. Caroline Pallard and Bart Swinkels investigate.

The Brazilian pharmaceutical sector: a year in review

Brazil01-05-2011Otto Licks and Anderson Nascimento

Practitioners can take heart from recent developments in the Brazilian courts, say Otto Licks and Anderson Nascimento.

Patentability of dosage regimens in Europe

France01-05-2011Stéphane Agasse

First instance courts in France have adopted controversial interpretations of an important Enlarged Board of Appeal decision, says Stéphane Agasse.

A revolution: biotech patents in India

India01-05-2011Archana Shanker

It has taken a long time for India to develop a productive environment for biotechnology. But recent developments look to have put it on the right track. Archana Shanker explains.

Recognising equivalence, reciprocity and respect

Canada, Mexico, US01-05-2011Hedwig Lindner and Manuel Morante

Homologation (recognition of equivalence) is a useful tool for simplifying administrative processes that are repeated in different countries. Nevertheless, it is not an end in itself.

Banning the patenting of biological materials in Australia: fact v fiction

Australia01-05-2011Tania Obranovich

An Australian legislative bill could have grave consequences for the country’s life sciences industry and, potentially, for patients as well. Tania Obranovich explains.

Windows of opportunity and closing doors at the EPO

EU01-05-2011Claire Baldock

There is a general acceptance that European patent law is complicated, particularly in the area of pharmaceutical inventions. Claire Baldock looks at how the EPO approaches these inventions.

Patenting life

EU01-05-2011Ashley Roughton

A case before the Court of Justice for the European Union threatens to radically redraw the patent landscape for embryonic stem cells. Ashley Roughton explains.

Showing 651 to 660 of 666 results

LSIPR